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A molecular signature of proteinuria in glomerulonephritis 
Abstract
Proteinuria is the most important predictor of outcome in glomerulonephritis and experimental data
suggest that the tubular cell response to proteinuria is an important determinant of progressive fibrosis in
the kidney. However, it is unclear whether proteinuria is a marker of disease severity or has a direct
effect on tubular cells in the kidneys of patients with glomerulonephritis. Accordingly we studied an in
vitro model of proteinuria, and identified 231 "albumin-regulated genes" differentially expressed by
primary human kidney tubular epithelial cells exposed to albumin. We translated these findings to
human disease by studying mRNA levels of these genes in the tubulo-interstitial compartment of kidney
biopsies from patients with IgA nephropathy using microarrays. Biopsies from patients with IgAN (n =
25) could be distinguished from those of control subjects (n = 6) based solely upon the expression of
these 231 "albumin-regulated genes." The expression of an 11-transcript subset related to the degree of
proteinuria, and this 11-mRNA subset was also sufficient to distinguish biopsies of subjects with IgAN
from control biopsies. We tested if these findings could be extrapolated to other proteinuric diseases
beyond IgAN and found that all forms of primary glomerulonephritis (n = 33) can be distinguished from
controls (n = 21) based solely on the expression levels of these 11 genes derived from our in vitro
proteinuria model. Pathway analysis suggests common regulatory elements shared by these 11
transcripts. In conclusion, we have identified an albumin-regulated 11-gene signature shared between all
forms of primary glomerulonephritis. Our findings support the hypothesis that albuminuria may directly
promote injury in the tubulo-interstitial compartment of the kidney in patients with glomerulonephritis.
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Introduction
Proteinuria is the clinical hallmark of glomerulonephritis, and
the most important predictor of outcome in both diabetes-related
and idiopathic glomerular-based kidney disease [1–8]. IgA
nephropathy (IgAN) is the most common form of primary kidney
disease world-wide [9,10]; up to 40% of patients with IgAN
progress to renal failure within 10 years of diagnosis [11]. Studies
have consistently shown that proteinuria is the most powerful
predictor of the rate of kidney function decline and kidney survival
in IgAN [12–17], and that in patients with IgAN, this relationship
is particularly strong even at low levels of proteinuria [18].
One of the pathologic features common to all forms of
progressive glomerular-based kidney disease is tubulo-interstitial
fibrosis, which shows consistent correlation with renal functional
impairment [19–21]. Tubulo-interstitial fibrosis may be triggered
by a variety of processes [22]; one proposed mechanism includes
exposure of tubular cells to protein. Experimental evidence
suggests that proteinuria is not only a marker of disease
progression, but is directly involved in the pathogenesis of
tubulo-interstitial fibrosis, and the progression of kidney injury
[23,24]. In patients with glomerular disease, proximal tubular
epithelial cells are exposed to pathologically high concentrations of
urinary proteins, including albumin. This induces a number of
potentially injurious biologic responses in tubular epithelial cells,
including inflammation, apoptosis, production of reactive oxygen
species, and transition to a myofibroblast phenotype, ultimately
contributing to tubulo-interstitial fibrosis [25–30]. These cellular
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responses may be dependent upon direct receptor-mediated
uptake of albumin by tubular epithelial cells and subsequent
stimulation of down-stream responses (such as NFkB-dependent
gene transcription) or endocytosis-independent activation of
signaling cascades by albumin [31]. While tubular cell exposure
to protein is not the only proposed mechanism by which
glomerular diseases result in tubulo-interstitial injury and progres-
sive loss of renal function [22,32], these observations may explain,
in part, the important relationship between proteinuria, tubulo-
interstitial injury, and long term outcome in glomerular-based
kidney disease [19–21,33].
Genome wide mRNA expression profiling tools, combined with
robust statistical approaches, provide an unbiased approach to
study the tubulo-interstitial transcriptional response initiated by
proteinuria [34]. Using this strategy, we have demonstrated in an
in vitro model of proteinuria that exposure of primary human renal
proximal tubular epithelial cells to albumin induces the differential
mRNA expression of a number of ‘‘albumin-regulated’’ genes,
including interleukin-8 (IL-8) and the epidermal growth factor
receptor (EGFR) [29]. Using this model system we demonstrated
that albumin exposure in vitro results in the enhanced expression of
IL-8 via activation of the mitogen-associated protein kinase ERK,
an effect that was dependent upon transactivation of the EGF
receptor and the generation of reactive oxygen species. While this
in vitro model is a highly simplified representation of the in vivo
disease process, in vitro findings using similar systems have been
confirmed in studies of human kidney disease [30,35].
To better understand the relationship between proteinuria and
tubular epithelial cell responses, we studied the expression of
‘‘albumin-regulated genes’’, defined in vitro, in the tubulo-
interstitium of human kidney biopsies from patients with
glomerulonephritis. First, primary human renal tubular epithelial
cells were exposed to albumin in vitro, and differential gene
expression was assessed using mRNA microarray analysis. A set of
231 differentially expressed ‘‘albumin-regulated’’ genes was
derived, and the expression of these genes was then measured in
the tubulo-interstitial compartment of kidney biopsy tissue from
patients with primary glomerulonephritis and healthy live kidney
donors. We first studied the expression of these transcripts in IgAN
biopsies, given that this is the most common type of primary
glomerulonephritis, and given the particularly close relationship
between proteinuria and kidney function in this disease [18]. We
then studied mRNA expression in the tubulo-interstitial compart-
ment of patients with other forms of idiopathic glomerulonephritis
to determine if there are shared mechanisms of tubulo-interstitial
injury.
Results
Differential gene expression in an in vitro model of
proteinuria
To determine the effect of albumin on gene expression in
cultured primary human renal tubular epithelial cells, mRNA
expression was measured using data from 8 microarrays (4 with
control conditions representing 8 experimental in vitro replicates,
and 4 BSA-treated conditions, representing 8 experimental
replicates). Using conservative thresholds for differential gene
expression, we identified 231 transcripts differentially expressed in
cells treated with 1% bovine serum albumin (BSA) versus control
conditions for 6 hours. A selection of the mRNA transcripts found
to be differentially expressed in this model, using stringent
statistical selection criteria, is provided in Table 1 (full list
Supplementary Data S1). Albumin-dependent mRNA regulation
was seen in genes involved in apoptosis, cell growth and
metabolism, cell-signaling, lipid metabolism, matrix turnover, cell
cycle, cell movement, lipid metabolism, and reactive oxygen
species scavenging.
Expression of ‘‘albumin-regulated genes’’ in human
kidney biopsy sample
Affymetrix microarray mRNA expression data were generated
from the tubulo-interstitial compartment of biopsies from 25
patients with IgAN and proteinuria and 6 control subjects enrolled
in the European Renal cDNA Bank Bank - Kro¨ner-Fresenius
biopsy bank (ERCB-KFB). The clinical characteristics of subjects
are shown in Table 2; subjects with IgAN had a wide range in
proteinuria (trace to 10g/day) and renal function (normal to stage
4/5 CKD). Expression data for 231 unique ‘‘albumin-regulated’’
genes (derived above) were extracted from the human renal biopsy
microarray data.
To determine if the expression levels of these 231 genes were
associated with the kidney disease process, hierarchical cluster
analysis of the expression data was performed (Figure 1). Cluster
analysis distinguished between renal biopsies from control subjects
and the renal biopsies from patients with IgAN based upon the
expression of the 231 ‘‘albumin-regulated genes’’. The cluster
analysis findings were not reproduced using the expression data of
randomly selected gene sets of similar size. Of the 231 genes, 49
(21%) were differentially expressed in the IgAN samples compared
to the healthy control samples (FDR 5%, see Supplementary Data
S1) compared to 4% of the genes in the complete Affymetrix data
(x2 = 147, p,0.01), confirming the enrichment of regulated genes
in the in vitro defined gene set.
A gene expression signature of proteinuria in IgAN
Given the critical relationship between proteinuria and outcome
in IgAN, even at low levels of proteinuria [18], we specifically
examined genes differentially expressed in IgAN biopsies com-
pared with control biopsies. The 231 gene set was derived from an
in vitro model of proteinuria designed to be representative of the
biologic response of kidney tubular cells in to proteinuria, so we
studied the relationship between the expression levels of the
‘‘albumin-regulated’’ genes in the tubulo-interstitial compartment
from the renal biopsies of the patients with IgAN with the level of
proteinuria at the time of kidney biopsy, and selected the mRNAs
with expression levels significantly correlated with proteinuria.
We then utilized the following criteria to select a list of genes for
the validation studies: 1) genes differentially expressed by human
renal tubular cells after exposure to albumin, in vitro; 2) genes
differentially expressed in the tubulo-interstitial compartment of
patients with IgAN compared to control subjects (this compart-
ment includes tubular epithelial cells, interstitial tissue and cells
such as fibroblasts, and endothelial cells in vascular structures)
based upon the biopsy Affymetrix microarray data set; 3) genes
with expression levels related to level of proteinuria within IgAN.
This selection process yielded a set of 11 genes (see Table 3).
Albumin-regulated genes in primary GN
In order to determine if the relationship between the expression
of the albumin-regulated genes and the kidney disease process is
unique to IgAN, the Affymetrix microarray mRNA expression
data for these genes were derived from the tubulo-interstitial
compartment of biopsies from patients with primary focal
segmental glomerulosclerosis (FSGS, n= 10), membranous GN
(MGN, n= 18) and minimal change disease (MCD, n= 5) and
proteinuria and 21 control subjects (healthy kidney donors with
normal renal biopsies) enrolled in the ERCB-KFB. The clinical
Proteinuria Gene Signature
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Table 1. Genes differentially expressed in cells exposed to albumin.
Genes related to apoptosis: p =0.02 Genes related to cell cycle: p =0.02 CONT’D
BIN1 bridging integrator 1 INHBA inhibin, beta A (activin A, activin AB alpha polypeptide)
CDK2AP1 CDK2-associated protein 1 KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1)
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)
CFLAR CASP8 and FADD-like apoptosis regulator PTHLH parathyroid hormone-like hormone TFDP1 transcription factor Dp-1
CROP cisplatin resistance-associated overexpressed protein TFDP2 transcription factor Dp-2 (E2F dimerization partner 2)
DAPK1 death-associated protein kinase 1 TYMS thymidylate synthetase
DUSP5,6 dual specificity phosphatase 5,6
GLRX glutaredoxin (thioltransferase) Cellular movement: p =0.02
HTRA2 HtrA serine peptidase 2 HMGB2 high-mobility group box 2
IER2 immediate early response 2 NR2F2 nuclear receptor subfamily 2, group F, member 2
IER3 immediate early response 3 RGS4 regulator of G-protein signaling 4
IGFBP3 insulin-like growth factor binding protein 3 S100A2 S100 calcium binding protein A2
MBD4 methyl-CpG binding domain protein 4 SPRY2 sprouty homolog 2 (Drosophila)
MCL1 myeloid cell leukemia sequence 1 (BCL2-related) SPRY4 sprouty homolog 4 (Drosophila)
NDRG1 N-myc downstream regulated gene 1
SFN stratifin Connective tissue development and metabolism: p=0.02
THBD thrombomodulin COL1A1 collagen, type I, alpha 1
CYR61 cysteine-rich, angiogenic inducer, 61
Cell growth and proliferation: p=0.03 KRT18 keratin 18
ADFP adipose differentiation-related protein PLAU plasminogen activator, urokinase
CCL20 chemokine (C-C motif) ligand 20 PLAUR plasminogen activator, urokinase receptor
DNAJC9 DnaJ (Hsp40) homolog, subfamily C, member 9 SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator
inhibitor type 1), member 1
HSPB8 heat shock 22kDa protein 8
IRF8 interferon regulatory factor 8 Lipid metabolism: p=0.02
SEMA4D sema domain, immunoglobulin domain (Ig), transmembrane
domain (TM) and short cytoplasmic domain, (semaphorin) 4D
ACSL3 acyl-CoA synthetase long-chain family member 3
UPP1 uridine phosphorylase 1 FDFT1 farnesyl-diphosphate farnesyltransferase 1
HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A reductase
Cell-to-cell signaling, interaction: p=0.003 HMGCS1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (soluble)
EGFR epidermal growth factor receptor (erythroblastic leukemia viral
v-erb-b oncogene homolog, avian)
LDLR low density lipoprotein receptor (familial hypercholesterolemia)
EGR1 early growth response 1 LIPG lipase, endothelial
ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific)
IGFBP3 insulin-like growth factor binding protein 3 Free radical scavenging: p=0.01
IL6 interleukin 6 (interferon, beta 2) TXNIP thioredoxin interacting protein
IL8 interleukin 8 XDH xanthine dehydrogenase
LIF leukemia inhibitory factor (cholinergic differentiation factor)
PBEF1 pre-B-cell colony enhancing factor 1 Other Genes of Interest
PHLDA2 pleckstrin homology-like domain, family A, member 2 BHLHB2 basic helix-loop-helid domain containing, class B,2
TNFSF10 tumor necrosis factor superfamily, member 10 CEBPD CCAT/enhancer binding protein, delta
KDELC1 KDEL (Lys-Asp-Glu-Leu) containing 1
Genes related to cell cycle: p =0.02 MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian)
CDC7 CDC7 cell division cycle 7 (S. cerevisiae) PSMD11 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11
CDC27 cell division cycle 27 SAMD4 sterile alpha motif domain containing 4
CDK4 cyclin-dependent kinase 4 SLC19A2 solute carrier family 19 (thiamine transporter) member 2
G0S2 G0/G1switch 2 STEAP1 6 transmembrane epithelial antigen of prostate 1
HBEGF heparin-binding EGF-like growth factor TARS threonyl-tRNA synthetase
HK2 hexokinase 2 ZBED5 zinc finger BED-type containing 5
HMOX1 heme oxygenase (decycling) 1
doi:10.1371/journal.pone.0013451.t001
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characteristics of subjects are shown in Table 4. As reference
samples healthy living kidney donors known to have normal renal
function and no proteinuria were used.
We found that the expression of these 11 mRNAs differed in the
tubulo-interstitial compartment of all biopsies of subjects with
primary glomerular disease compared to controls. Hierarchical
cluster analysis confirmed that renal biopsies from healthy donors
can be distinguished from the renal biopsies of patients with all
forms of primary GN based solely upon the expression of the 11
mRNA gene signature (Figure 2). Cluster analysis using expression
data of randomly selected gene sets of similar size did not
distinguish kidney biopsies of control subjects from the biopsies of
subjects with GN.
Potential common regulatory pathways
To define the functional context of the proteinuria associated
genes, a transcriptional network was constructed using a co-
citation natural language processing (NLP) tools (Genomatix
Bibliosphere), considering all of the transcripts of the 11-gene
mRNA signature (Supplementary Data S1). EGR1 emerged as a
central node linking EGR1 to the remaining 10 mRNA
transcripts. To determine if common transcription factor promoter
elements could explain the functional relationship between these
11 albumin-regulated mRNA transcripts, promoter regions (500bp
up and 100bp downstream of the transcription start sites) was
performed (Genomatix Bibliosphere). In concordance with the
central role of the EGR node in the NLP analysis, most of the
genes encoding the 11-gene mRNA signature contain a proximal
EGR1 promoter regions, consistent with a putative common
transcriptional regulation (Figure 3).
Discussion
Proteinuria is an important determinant of outcome in primary
GN but the mechanisms responsible for this association have not
been fully elucidated. Although in vitro and experimental studies
suggest that proteinuria, and in particular albumin, elicits a
biological response in kidney tubule epithelial cells that contributes
to progressive tubulointerstitial injury [35], it is uncertain if
proteinuria has a direct effect on gene expression in human kidney
disease. Development of new unbiased molecular and statistical
tools for studying mRNA expression in renal tissue has greatly
advanced our ability to study renal disease, and to translate
findings from basic molecular and cell biology research to human
disease [34,36–44]. Accordingly, the aim of this study was to test
the hypothesis that there is a steady-state change in gene
expression in the renal tubulointerstitium of subjects with primary
GN that reflects a biological response of the tubule cells to
proteinuria.
In order to address this hypothesis we exposed primary human
renal proximal tubular epithelial cells to albumin, in vitro,
simulating the exposure of tubular cells to proteinuria in human
proteinuric glomerulonephritis. Our first major finding was the
identification of a distinct set of 231 mRNAs differentially
regulated in human renal tubular cells by albumin exposure in
vitro (Supplementary Data S1). Gene ontology (GO) analysis
identified several pathways that were statistically over-represented
in the in vitro expression data, and the proteins encoded by these
genes are involved in diverse biological processes including
apoptosis, cell cycling, pro-inflammatory cell signaling cytokines,
connective tissue development and fibrosis, and free radical
scavenging, and lipid metabolism (Table 1).
Although the genes regulated by albumin in vitro can be related
to injury pathways and outcomes like cell loss, inflammation, and
fibrosis, we sought to translate these findings to human kidney
disease by comparing the expression levels of these genes in the
kidneys of normal subjects and subject with primary GN. mRNA
levels were measured by microarray analysis in the microdissected
tubulointerstitial compartment of renal biopsy samples in order to
capture the kidney tubular cell transcriptome in vivo. We chose to
focus first on subjects with IgAN because new evidence has shown
that incremental increases in proteinuria are associated with
dramatic reductions in renal survival in IgAN [18], and that in
patients with IgAN, these changes occur at far lower levels of
proteinuria compared to patients with other forms of primary GN
[45]. Our second major finding was that we could distinguish
between the kidney biopsies of subjects with IgAN and healthy
living donors based solely upon the tubulo-interstitial expression
levels of the 231 ‘‘albumin-regulated genes’’ using hierarchical
cluster analysis.
In order to determine if this clustering phenomenon was a
chance event, we tested random sets of 231 genes generated from
the full Affymetrix expression dataset but cluster analysis of these
random gene sets failed to segregate IgAN from control biopsies.
In addition, we found significantly enriched differential expression
of the 231 ‘‘albumin-regulated genes’’ in the tubulo-interstitial
tissue of IgAN biopsies compared to control biopsies. Taken
together, these analyses support the hypothesis that the biological
response to albumin that we observed in vitro may also be present,
at least in part, in the kidneys of subjects with IgAN and
proteinuria.
In order to further explore the link between proteinuria and
gene expression in vivo, we then studied the relationship between
the expression levels of the 231 genes and the levels of proteinuria
at the time of biopsy within the group of subjects with IgAN. The
rationale for this analysis was twofold: first, proteinuria is known to
be the most powerful predictor of outcome in glomerular-based
diseases, including IgAN, and, second, the tubular response to
proteinuria (modeled by our in vitro experiment) may be a key
factor determining progressive tubulo-interstitial fibrosis and
nephron loss, important pathologic indicators of prognosis in
IgAN [11,18]. Our third major finding was that the tubulo-
interstitial expression levels of 11 mRNA transcripts (of the 231
albumin-regulated genes) correlated significantly with the level of
proteinuria at the time of biopsy, suggesting that there may be a
biological relationship between gene expression in the tubuloin-
terstitial compartment of the kidney and proteinuria. We labeled
this set of 11 genes the ‘‘proteinuria signature’’.
The 11 genes in the ‘‘proteinuria signature’’ encode some
proteins previously implicated in the tubular response to
proteinuria, as well as some proteins that have not been studied
Table 2. Patient characteristics – subjects with IgA
nephropathy.
Control IgA nephropathy
Number 6 25
Mean age
(range)
48.5
(32–62)
36
(19–84)
% male 50 71
Mean serum creatinine 6 SD (range)
mmol/L
,120 1316129 (40–643)
Mean 24h urine protein 6 SD (range)
g/24h
,0.20 2.3662.3 (0.28–10)
doi:10.1371/journal.pone.0013451.t002
Proteinuria Gene Signature
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13451
in the context of kidney disease, and thus may be potential new
mediators of progressive kidney injury. For example, protein
members of the coagulation cascade have been implicated in
extracellular matrix protein turnover in the kidney, and we found
that Serpine1 (PAI-1) was a transcipt identified in the proteinuria
signature. Serpine1 is not normally produced in the kidneys,
however experimental evidence suggests that it is an important
promoter of renal fibrosis [46]. The mechanisms by which it
promotes fibrosis are not entirely elucidated, however in addition
to inhibiting protease activity in the extracellular compartment, it
may modulate inflammatory cell recruitment, and fibroblast
activation [47]. Work in experimental models of kidney disease
including protein overload injury, proliferative glomerulonephritis,
and obstructive kidney disease suggests that increased PAI-1
expression is associated with interstitial fibrosis, and reduction in
PAI-1 expression (via drug therapy or recombinant techniques) is
associated with attenuation of renal fibrotic injury [46–50].
Furthermore, de novo PAI-1 protein expression is documented
Figure 1. Cluster analysis. Clustering of microarrays according to disease status (horizontal axis) based upon expression of the 231 albumin-
regulated genes (vertical axis). Control = control group, IgAN= IgA nephropathy.
doi:10.1371/journal.pone.0013451.g001
Proteinuria Gene Signature
PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13451
in kidney biopsies of patients with glomerular based kidney disease
[51–53]. Our data support the hypothesis that proteinuria may
contribute to fibrosis by increasing PAI-1 expression by tubular
cells. In addition, the early growth response gene 1 (EGR-1) has
been implicated in the TGFb-mediated fibrosis [54] and in the
regulation of interstitial fibrosis in the experimental unilateral
ureteric obstruction model [55]. Finally, our discovery that the
gene for collagen I, alpha 1, was also in the ‘‘proteinuria
signature’’ also supports a link between proteinuria, gene
expression in the tubulointerstitium, and fibrosis.
In addition to interstitial fibrosis, apoptosis of tubular cells
contributes to progressive kidney injury in primary GN by
promoting cell loss [56,57]. In this regard, EGR-1 has also been
reported to regulate apoptosis in response to oxidative stress [58].
Two other apoptosis-related genes, immediate early response 3
(IER3) and myeloid cell leukemia sequence 1 (MCL1), were also in
the 11 gene ‘‘proteinuria signature’’. The MCL1 gene encodes a
member of the bcl2 family that may promote or inhibit apoptosis
depending on the tissue [59–61]. For example, MCL1 has been
found to support cell survival in Wilms’ Tumour cell lines [62].
Neither MCL1 nor IER3 have been studied in the context of
primary GN, and further studies will be necessary to better define
their role in kidney disease. Similarly, the role of the proteins
encoded by genes MAFF, TYMS, and SAMD4A in the
progression of GN is unknown.
The next goal of this study was to determine if these 11 genes
represented a generic response to proteinuria that was present in
other forms of primary GN because our in vitro experiments
identified a response of tubular cells to albumin that was
independent of glomerular injury. In order to address this
question, we studied the expression levels of the 11 genes in
kidney biopsy samples from subjects with three other common
forms of primary GN: focal segmental glomerulosclerosis (FSGS),
membranous nephropathy (MGN), and minimal change disease
(MCD). The biopsies of subjects with FSGS, MGN, and MCD
could be distinguished from control biopsies based solely upon the
expression of the 11-gene signature, supporting the conclusion that
this 11-gene set is part of a common pathway linking proteinuria
to gene expression in the kidney.
Finally, we subjected the 11 genes to a bioinformatics analysis in
order to explore relationships between the component genes in the
‘‘proteinuria signature’’. We first constructed a transcriptional
network (Supplemental Figure S1 in Supplementary Data S1)
utilizing Genomatix Bibliosphere. The network derived from this
analysis placed EGR1 in the central node. Based on this finding, we
then went on to perform a transcription factor analysis utilizing gene
promoter sequence data for the 11 genes, and we found that the
consensus sequence for EGR1 was present in 6 of the genes in the
‘‘proteinuria signature’’. This analysis suggests that EGR1 may play
a key role in a common pathway orchestrating the transcriptional
response kidney tubule cells to proteinuria in vivo. The transcription
factor analysis further suggests that the transcription factor ELF3
may also mediate this response, at least in part.
There are some important limitations in the current study. First,
stringent and conservative statistical thresholds were used in the
initial selection of differentially expressed genes in vitro at a single
time point of 6-hours of albumin exposure. This design may have
precluded identification of other important genes involved in the
tubular cell response to albumin exposure (Type II Error). In
addition, we used the in vitro data set for a targeted analysis of the
human subjects with GN, capturing a different gene set than that
identified by Rudnicki et al. [63] in studies of laser-microdissected
proximal tubular cells in GN.
Table 3. Validation gene set.
Gene Title Gene Symbol Biological Process Description
collagen, type I, alpha 1 COL1A1 skeletal development, epidermis development
early growth response 1 EGR1 regulation of transcription, T cell differentiation
E74-like factor 3 (ets domain transcription factor,epithelial-specific) ELF3 regulation of transcription, epidermis development,
morphogenesis
immediate early response 3 IER3 Anti-/apoptosis, morphogenesis
heparin-binding EGF-like growth factor HBEGF Signal transduction, EGFR signaling pathway, smooth muscle cell
proliferation
v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) MAFF transcription regulation, epidermal cell differentiation
myeloid cell leukemia sequence 1 (BCL2-related) MCL1 regulation of apoptosis, differentiation
sterile alpha motif domain containing 4A SAMD4A positive regulation of translation
serpin peptidase inhibitor (plasminogen activator inhibitor type 1)1 SERPINE1 blood coagulation, fibrinolysis, regulation of angiogenesis
six transmembrane epithelial antigen of the prostate 1 STEAP1 electron transport
Thymidylate synthetase TYMS nucleic acid metabolism/biosynthesis, DNA replication/repair,
phosphoinositide-mediated signaling
doi:10.1371/journal.pone.0013451.t003
Table 4. Patient characteristics – European Renal cDNA Bank
glomerular disease subjects.
FSGS MGN MCD
Number 10* 18 5**
Mean age (range) 50 (32–76) 53 (18–86) 45 (25–78)
% male 60 56 80
Mean serum creatinine
6 SD (range)
mmol/L
1566105
(53–355)
88.6635.5
(40–160)
101642.5
(53–134)**
Mean 24h urine protein
6 SD (range)
g/24h
4.9762.6
(1.9–8.4)
4.5863.2
(0.5–9.8)
2.9064.0
(0.1–5.7)
*10 patients age available for only 4 patients.
**5 patients; age and serum creatinine available for only 3 patients.
doi:10.1371/journal.pone.0013451.t004
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Finally, while we derived our list of candidate genes from an in
vitro model of proteinuria, it is likely that the transcriptional
response of the genes measured in the tubulo-interstitium of the
kidney biopsies is not due entirely to exposure to albumin the
ultrafiltrate. We may also be capturing the tubular response to
other factors that play a role in progression. For example, it is
possible that the transcriptional response is related to exposure of
tubular cells to filtered growth factors [64], other proteins in the
ultrafiltrate, or modified albumin moieties [42,65–69]}. In this
regard, Kritz and coworkers have suggested that albumin uptake
by tubular cells is not an absolute prerequisite for tubulo-intertitial
injury in mice with glomerulonephritis [32]. Other contributors to
nephron loss in glomerular-based kidney disease include misdi-
rected filtrate and obstruction of the tubulo-glomerular junction
with subsequent tubular cell injury and ischemia [22,32]. The
importance of multifactorial contributions to tubulo-interstitial
fibrosis beyond tubular cell albumin exposure is highlighted by the
clinical observation that in IgAN, tubulo-interstitial injury and
functional decline occurs at far lower levels of proteinuria [45]. Of
interest, our mRNA signature was able to discriminate minimal
change nephropathy biopsies from control samples, despite the
fact that this entity is only more rarely associated with tubulo-
interstitial fibrosis and progressive functional loss [70]. However,
when proteinuria reduction is not achieved in patients with this
disease, sclerosis, fibrosis, and functional loss does occur [70].
It is also possible that the tissue mRNA signature is not entirely
derived from tubular cells. There are little morphometric data that
quantify the relative abundance of cells that comprise the cortical
Figure 2. Cluster analysis. Clustering of microarrays according to disease status (columns) based upon expression of the 11 albumin-regulated
genes (rows). Control = control group, FSGS= focal segmental glomerulosclerosis, MGN=membranous GN, MCD=minimal change disease.
doi:10.1371/journal.pone.0013451.g002
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interstitium in the disease state. In ‘‘normal’’ control biopsies, 87%
of the tubulo-interstitial compartment is comprised of the tubular
cell component; in biopsies of patients with type 1 diabetes with
early nephropathy, this reaches 91% [71]. The non-tubular cell
component comprises only 13% of the healthy cortex or less [72].
Of the non-tubular cell portion, only 14% (ie. ,2% total) is
composed of peritubular capillaries, in biopsies with moderate
interstitial expansion due to diabetic nephropathy [71,72]. Taken
together, these data suggest that the predominant resident cell
transcriptome signal is derived from tubular cell mRNA
expression. Emerging evidence also suggests that number of
dendritic cells in the cortical tubulo-interstitium of kidney biopsies
from patients with glomerulonephritis is increased in comparison
to control biopsies [73], and appear to contribute to progressive
kidney disease in animal models [74]. Interstitial macrophage
infiltration occurs in many forms of primary glomerulonephritis;
while data suggest that cellular infiltration correlates with renal
function at the time of biopsy, the relationship to proteinuria is not
as clear (reviewed in [75]). We cannot discount the possibility that
these cells are also contributing to the mRNA expression profile.
In summary, we have used an in vitro model of proteinuria to
identify a set of ‘‘albumin-regulated genes’’ in primary human
renal tubular cells. We have translated these findings to human
primary GN, and identified a subset of mRNA transcripts with
expression levels that correlate with the level of proteinuria, and
that distinguish biopsies of subjects with GN from biopsies of
control subjects. Further studies will be necessary to define the
biological role of these genes in proteinuric kidney disease and to
determine if measures of expression of these genes are predictive of
long-term clinical outcome.
Methods
Primary cell culture system
The cell system used was previously described [29]. Eight flasks
of primary human renal tubular epithelial cells (Cambrex,
Walkersville, MD) were exposed to medium alone and 8 flasks
of cells were exposed to medium containing 1% bovine serum
albumin for 6 h. The RNA extracted (Qiagen RNeasy kit,
Valencia, CA); RNA from cells grown in two flasks was pooled
to form one experimental sample, and each experiment was
performed in quadruplicate (total 16 flasks for eight microarrays—
four arrays from control cell RNA and four arrays from albumin-
treated cell RNA). RNA quality was verified using the Agilent
bioanalyzer (Agilent Technologies, Palo Alto, CA).
Synthesis of cDNA and array hybridization, washing, and
scanning were performed by the Affymetrix Gene Chip core
facility at The Centre for Applied Genomics at Toronto’s Hospital
for Sick Children (Ontario, Canada) according to Affymetrix-
recommended protocols (Santa Clara, CA) using the hgu 133A
Affymetrix Gene Chip and an Affymetrix Fluidics station.
RNA extraction and mRNA expression profiling of human
renal biopsy tissue
The study was performed as outlined previously in detail
[36,40]. Human renal biopsy specimens were procured in an
international multicenter study, the European Renal cDNA Bank-
Kro¨ner-Fresenius biopsy bank (ERCB-KFB, see acknowledge-
ments for participating centers) [36]. Renal biopsies were obtained
after written consent and approval of the ethics committee and in
the frame of the ERCB-KFB approved by the specialized
subcommittee for internal medicine of the cantonal ethics
committee of Zurich. The characteristics of patients are shown
in Table 2. Control biopsy samples were obtained during the cold
ischemia period of living-related donor transplantation.
Total RNA was extracted from manually microdissected tubulo-
interstitial compartments obtained from living donors (n = 6) and
patients with IgA nephropathy (n= 25). After one round of
amplification of 300–800 ng of total RNA, RNA quality and
quantity was verified (Agilent Technologies, Waldbronn, Ger-
many). The fragmentation, hybridization, staining and imaging
was performed according the manufacturer’s guidelines (Affyme-
trix). For a detailed description of the protocol see reference [44].
All microarray data are MIAME compliant as detailed on the
MGED Society website http://www.mged.org/Workgroups/
MIAME/miame.html. The raw data will be GEO accessible
through GEO Series accession.
II. Data filtering strategy to determine renal response to
proteinuria
In order to rationally filter the large volume of data derived
from the microarray experiments, the following strategy was
employed to select the genes that are characteristic of the renal
response to proteinuria:
N 1 – Identification of genes differentially expressed in the in vitro
model of proteinuria by SAM and Limma analysis (described
below).
N 2 – Identification of genes differentially expressed in the
mRNA expression profiling data from tubulo-interstitial tissue
of patients with IgA nephropathy vs. control samples.
N 3 – Identification of genes correlating with and predictive of
proteinuria in vivo by linear models using Limma and lasso
regression procedure, respectively.
Figure 3. Transcription factor analysis. Green shade indicates the
presence of a transcription factor binding site sequence, upstream from
the gene of interest. Each row represents a gene of interest, and each
column represents a putative transcription factor.
doi:10.1371/journal.pone.0013451.g003
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Statistical tools employed for data analysis
The microarray data obtained from the in vitro model were
examined and visualized using Affymetrix Microarray Suite 5.0
software and Bioconductor [76,77]. The calculation of expression
values from probe intensities and normalization of arrays was
performed using the RMA method [78] using Bioconductor and
RMAexpress [79] (accessed 2006). Differential gene expression was
determined using Limma (Linear models for microarray data) and
SAM (Significance Analysis of Micoarrays) through Bioconductor
[80,81], with a highly conservative false-discovery rate set at 0.01,
and genes were not filtered based upon an arbitrarily-selected fold-
change in expression. Differential expression was assessed in the in
vivo tubulo-interstitial samples using SAM and dChip [82].
Cluster analysis was performed using Sammon mapping/multi-
dimensional scaling, as well as spectral clustering [83] for
experimental cell data, and hierarchical cluster analysis was
performed using dChip [82,84] in the renal biopsy dataset
(centroid-based, distance metric: 1-correlation).
In order to explore the ontology of genes differentially expressed
in vitro, genes were ranked by limma topTable function (by
adjusted p-value), and 600 up and down-regulated genes were
selected to study possible common ontology patterns. Enriched
expression of gene ontology (GO) terms was assessed with
Ingenuity Pathway Analysis Software 4.2 (Redwood City, CA)
and confirmed using the Bioconductor package GOstats. These
programs determine which gene ontology terms found in gene lists
are statistically over or under represented, compared with the GO
terms represented in the microarray as a whole [85,86]. A list of
enriched GO terms is produced, including the test statistic and
associated p value, suggesting functional mechanisms that may
underlie the biological response captured in the data set.
Clinical data were extracted for the patients who underwent
renal biopsy and inspection revealed that proteinuria values and
residuals were skewed, and should be normalized by log
transformation for regression analysis. To select transcripts with
mRNA expression most closely related to proteinuria in IgAN,
mRNA expression was correlated with proteinuria in vivo using
advanced regression analysis with linear models (with limma and
topTable function in Bioconductor) [81]. Partitioning methods
were also employed to use the biopsy gene expression data to
predict proteinuria. Lasso regression procedure was also used to
confirm genes that were most predictive of log proteinuria tuned
by a 10-fold cross-validation procedure [87].
Once this filtration strategy was applied, and the 11-mRNA
signature identified, the normalized mRNA expression data were
then extracted from the full datasets from MGN, FSGS, and MCD
biopsies. Hierarchical cluster analysis was performed on the human
renal biopsy data set using dChip [82] (centroid-based, distance
metric: 1-correlation). Tests of the correlation between proteinuria
and mRNA expression were performed by relating the normalized
mRNA expression values to proteinuria using Pearson correlation.
Supporting Information
Dataset S1 A molecular signature of proteinuria in
glomerulonephritis.
Found at: doi:10.1371/journal.pone.0013451.s001 (0.86 MB
DOC)
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